Chengdu Bio: Plans to establish a 1 billion yuan industrial fund with major shareholders and increase the capital of target companies.

Chengda Biology announced that the company plans to jointly establish the Chengda Biomedical Industry Investment Fund with its controlling shareholder Liaoning Chengda, its wholly-owned subsidiary Chengda Coastal, and the company's wholly-owned subsidiary Shenzhen Chengda Biology, with a total size not exceeding 1 billion Yuan and an initial size of 502 million Yuan. The company will subscribe for 400 million Yuan with its own funds, accounting for 79.6813% of the fund shares at the time of establishment. Additionally, Shenzhen Chengda Biology plans to increase its investment in GeneMD based on the contribution ratio, and after the fund is established and filed, the fund will acquire all the equity of GeneMD held by the two parties at a fair price. Furthermore, the company plans to amend its "Articles of Association" and its appendices. The above matters all require approval by the shareholders' meeting.